Education
About Us
Working with TipRanks
Follow Us
Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
Top Page
Autolus Therapeutics
(NASDAQ:AUTL)
Select Model
Select Model
Rating:55Neutral
Price Target:
$1.50
▼(-4.46% Downside)
Autolus Therapeutics' overall score reflects its strong market penetration and capitalization, offset by significant financial challenges. The technical indicators show some positive momentum, but valuation concerns persist due to ongoing losses.
Positive Factors
Revenue Growth
Significant revenue growth indicates strong demand for Autolus' products and successful commercialization efforts, supporting long-term sustainability.
Strong Market Penetration
Increased market penetration reflects Autolus' competitive positioning and potential for further expansion, enhancing its market presence.
Cash Reserves
Strong cash reserves provide financial stability and flexibility to fund ongoing R&D and commercialization efforts, supporting growth strategies.
Negative Factors
High Cost of Sales
High cost of sales relative to revenue indicates inefficiencies that could pressure margins and profitability, challenging long-term financial health.
Operational Losses
Continued operational losses highlight challenges in achieving profitability, which may hinder long-term financial sustainability and growth.
Negative Cash Flow
Negative cash flow indicates reliance on external funding, which could limit financial flexibility and increase risk if funding sources become constrained.
Autolus Therapeutics (AUTL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$415.18M
Dividend YieldN/A
Average Volume (3M)3.41M
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth407.86%
EPS Growth30.35%
CountryUS
Employees647
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.30
Shares Outstanding266,143,280
10 Day Avg. Volume2,797,438
30 Day Avg. Volume3,407,039
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.40
Price to Sales (P/S)59.25
P/FCF Ratio-2.49
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue7.63
Enterprise Value/Gross Profit-2.47
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$7.68Price Target Upside389.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.92
Revenue Forecast (FY)$75.20M
Autolus Therapeutics Business Overview & Revenue Model
Company DescriptionAutolus Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation T cell therapies for the treatment of cancer. The company specializes in engineered T cell therapies, leveraging its proprietary technology platforms to create innovative products aimed at addressing significant unmet medical needs in oncology. Autolus is dedicated to advancing its pipeline of product candidates through clinical trials, primarily targeting hematological malignancies and solid tumors.
How the Company Makes MoneyAutolus Therapeutics generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which provide funding for research and development activities in exchange for rights to commercialize products developed from Autolus' technology. Additionally, the company may receive milestone payments as its product candidates progress through clinical trials and regulatory approvals. While Autolus is primarily in the development phase and may not yet have substantial product sales, revenue can also be derived from licensing agreements and grants to support its ongoing research initiatives.
Autolus Therapeutics Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 10, 2026
Earnings Call Sentiment Neutral
While the company has seen a successful launch of Obe-cel in the U.S. with significant market penetration and expansion into new clinical areas, financial challenges such as high cost of sales and increased operational losses present notable challenges. However, the company is well-capitalized to continue its growth and expansion strategies.Q3-2025 Updates
Positive Updates
Successful Launch of Obe-cel in the U.S.
Achieved $21.1 million in net sales in the third quarter, with a total of $51 million in sales in the first nine months. Established 60 authorized centers across the U.S. with a manufacturing success rate well above 90%.
Strong Market Penetration and Growth Potential
CAR T market share increased to approximately 20% in active centers. Significant opportunity for growth within existing centers and geographic expansion.
Clinical Trials and Pipeline Expansion
Initiated a pivotal phase two study in pediatric ALL, a phase two study in lupus nephritis, and an exploratory phase one study in progressive multiple sclerosis.
Positive Financial Position
The company remains well-capitalized with cash, cash equivalents, and marketable securities totaling $36.067 billion as of September 30, 2025.
Negative Updates
High Cost of Sales
Cost of sales totaled $28.6 million, exceeding the product revenue of $21.1 million, indicating room for improvement in efficiency and cost management.
Increased Selling and Administrative Expenses
Selling and general administrative expenses rose to $36.3 million in Q3 2025, up from $27.3 million in the same period in 2024, driven by increased headcount for commercialization activities.
Continued Operational Losses
Loss from operations was $71.6 million and net loss was $79.1 million for the three months ending September 30, 2025, reflecting ongoing financial challenges.
Company Guidance
During the third quarter of 2025, Autolus Therapeutics plc reported $21.1 million in net sales for their product Obe-cel, with a deferred revenue of $7.6 million. The company achieved sales of $51 million over the first nine months of the year and authorized 60 treatment centers, meeting their target. Their manufacturing success rate exceeded 90%, and patient access covered more than 90% of U.S. lives. The company is focusing on optimizing operations to improve margins and expand their market beyond adult ALL. Plans include a pivotal study in pediatric ALL, a phase two study in lupus nephritis, and a phase one study in progressive multiple sclerosis. The net loss for the quarter was $79.1 million, a reduction from $82.1 million in the previous year, with cash and marketable securities totaling $36.067 billion as of September 30, 2025.Autolus Therapeutics Financial Statement Overview
Summary
Autolus Therapeutics shows strong revenue growth but struggles with profitability and cash flow. The balance sheet is solid with low leverage and substantial cash reserves, yet operational losses and negative cash flows are significant challenges.Income Statement
Autolus Therapeutics has shown significant revenue growth in recent years, with a notable increase from $1.7M in 2023 to $10.1M in 2024. However, the company continues to report negative gross and net profit margins, indicating ongoing challenges in achieving profitability. The EBIT and EBITDA margins are also negative, reflecting substantial operational losses.25
Negative
Balance Sheet
The company's balance sheet highlights a strong equity position, with a substantial cash reserve relative to its liabilities. The debt-to-equity ratio is low at 0.12, suggesting limited leverage, but the company has consistently negative net income affecting ROE, which remains negative. The equity ratio is relatively stable, indicating a solid asset structure.40
Negative
Cash Flow
Autolus Therapeutics is facing challenges with negative free cash flow, which has worsened in recent periods. Although operating cash flow is negative, it is supported by financing activities, indicating reliance on external funding. The free cash flow to net income ratio is unfavorable, reflecting difficulties in converting income into cash.30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 51.13M | 10.12M | 1.70M | 6.19M | 1.51M | 1.72M |
| Gross Profit | -158.22M | -130.90M | 1.70M | 6.19M | 1.51M | -133.17M |
| EBITDA | -250.91M | -233.07M | -156.77M | -132.24M | -132.47M | -162.58M |
| Net Income | -224.80M | -220.66M | -208.38M | -148.84M | -142.10M | -142.09M |
Balance Sheet | ||||||
| Total Assets | 661.95M | 782.73M | 375.38M | 490.27M | 405.56M | 294.24M |
| Cash, Cash Equivalents and Short-Term Investments | 367.41M | 588.02M | 239.57M | 382.44M | 310.34M | 154.09M |
| Total Debt | 65.83M | 52.63M | 52.97M | 24.26M | 68.01M | 54.16M |
| Total Liabilities | 396.50M | 355.40M | 263.91M | 191.60M | 92.24M | 84.20M |
| Stockholders Equity | 265.45M | 427.32M | 111.47M | 298.67M | 313.32M | 210.03M |
Cash Flow | ||||||
| Free Cash Flow | -278.04M | -241.09M | -156.57M | -123.15M | -126.72M | -132.44M |
| Operating Cash Flow | -254.18M | -206.27M | -145.59M | -112.31M | -117.86M | -117.76M |
| Investing Cash Flow | -311.67M | -394.55M | -10.99M | -10.84M | -8.86M | -14.68M |
| Financing Cash Flow | 27.46M | 589.55M | -883.00K | 223.61M | 284.06M | 74.42M |
Autolus Therapeutics Technical Analysis
Neutral
1.57
Price Trends
1.49
Positive
1.60
Negative
1.72
Negative
Market Momentum
0.05
Negative
56.00
Neutral
51.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUTL, the sentiment is Neutral. The current price of 1.57 is above the 20-day moving average (MA) of 1.47, above the 50-day MA of 1.49, and below the 200-day MA of 1.72, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 56.00 is Neutral, neither overbought nor oversold. The STOCH value of 51.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AUTL.
Autolus Therapeutics Risk Analysis
Autolus Therapeutics disclosed 86 risk factors in its most recent earnings report. Autolus Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Autolus Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $415.18M | -1.86 | -60.52% | ― | 407.86% | 30.35% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $296.14M | -1.78 | -78.24% | ― | ― | -67.41% | |
47 Neutral | $365.37M | -11.32 | -43.71% | ― | ― | 80.95% | |
42 Neutral | $427.56M | -11.59 | -64.12% | ― | ― | -29.73% | |
39 Underperform | $419.36M | -5.05 | -30.40% | ― | ― | -100.71% | |
38 Underperform | $37.06M | -0.39 | -97.61% | ― | -53.67% | 86.75% |
* Healthcare Sector Average
AUTL
Autolus Therapeutics
1.57
-0.72
-31.44%
TVRD
Tvardi Therapeutics
3.89
-11.32
-74.42%
LRMR
Larimar Therapeutics
3.43
-0.58
-14.46%
BNTC
Benitec Biopharma
11.38
-0.03
-0.26%
DMAC
Diamedica Therapeutics
8.31
1.90
29.64%
CTNM
Contineum Therapeutics, Inc. Class A
11.39
-2.11
-15.63%
Autolus Therapeutics Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Autolus Therapeutics Appoints Ryan Richardson to Board
Positive
Dec 2, 2025
On December 1, 2025, Autolus Therapeutics announced the appointment of Ryan Richardson as a Class I director on its Board of Directors. Mr. Richardson, who has over 20 years of experience in healthcare and investment banking, previously served as Chief Strategy Officer at BioNTech SE, where he played a significant role in the company’s global expansion and transition to a commercial stage. His expertise is expected to aid Autolus in its growth as a commercial-stage company, particularly in expanding the reach of its therapy, obe-cel, in new indications.
Executive/Board ChangesBusiness Operations and StrategyFinancial Disclosures
Autolus Therapeutics Appoints New Principal Accounting Officer
Neutral
Nov 12, 2025
On November 7, 2025, Autolus Therapeutics announced the resignation of Rob Dolski as Principal Accounting Officer, with Patrick McIlvenny appointed to the role effective the same day. The company reported third-quarter 2025 financial results, including $21.1 million in net product revenue for AUCATZYL® and 60 authorized treatment centers. Autolus is advancing its obe-cel therapy for pediatric r/r B-ALL and severe lupus nephritis, with promising clinical data and FDA designations supporting further trials. Leadership changes aim to bolster commercial growth and operational efficiency.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.